Table 2 Vaccine Trials for Glioma Patients
From: Cellular and vaccine therapeutic approaches for gliomas
Center/Investigator | Therapy/Protocol | Phase - Enrollment | ND, P, R* | WHO Grade ** | Clinicaltrials.gov identifier | References |
|---|---|---|---|---|---|---|
Cell-Based Vaccines | Â | Â | Â | Â | Â | Â |
UCLA, Los Angeles, CA/L Liau | Autologous DC + Tumor Lysate | I - 36 | ND | III or IV | NCT00068510 | Liau et al [46] |
Cedars-Sinai, Los Angeles, CA/S Phuphanich | Autologous DC + Synthetic Glioma Peptide | I - 39 | R, P | IV | NCT00576641 | *** |
Duke Univ, Durham, NC/D Mitchell | Autologous DC + Brain Tumor Stem Cell-mRNA | I - 50 | R | IV | NCT00890032 | Â |
Mass General, Boston, MA/W Curry Dana Farber, Boston, MA/P Wen | Autologous Tumor Cells + Irradiated GM-CSF Producing K562 Cells | I - 25 | R | III or IV | NCT00694330 | Â |
Non-cell Based Vaccines | Â | Â | Â | Â | Â | Â |
Duke Univ, Durham, NC/D Mitchell | CDX-110 (EGFRviii) Peptide Conjugate + TMZ ± Daclizumab | I/II - 20 | ND | IV | NCT00626015 | Heimberger et al [74] |
Pittsburgh Cancer Center, Pittsburgh, PA/F Lieberman | GAA peptides + PolyICLC | 0 - 9 | R | II | NCT00874861 | Butowski et al [75] **** |
Pittsburgh Cancer Center, Pittsburgh, PA/F Lieberman | GAA/TT-peptides + PolyICLC + Montanide ISA-51 | 0-6 | R | II | NCT00795457 | Â |
UCSF, San Francisco, CA/A Parsa | Autologous HSPPC-96 vaccine | I/II - 50 | R | IV | NCT00293423 | Yang & Parsa [76] |
UCSF, San Francisco, CA/A Parsa | Autologous HSPPC-96 ± TMZ | II - 63 | ND | IV | NCT00905060 |  |